Macroaxis: Personalized Investing
Simple Personalized Investing

SP 500   1,666   1.18  Index Moved Down -0.07%
VRX ELN HSP ALKS Long-Short Computers Services Conglomerates 
United States GSPC USD ...  |  Investing Themes


Processing
Collecting data for IPCI

IntelliPharm quote and profile

 
 Companies |  Insiders  | Dashboard  
     
1.79
  
STOCK
0.00  No Change   0.00%  
Year To Date
1.573.49
Last 1 Month(s)
1.772.2
May 21 2013 

Diversification Suggestion

Use IntelliPharm to protect against small markets fluctuations. The stock experiences normal downward trend, but the immediate impact on correlations cannot be determined at the moment
Analyze IntelliPharmaCeutics Trend or Check current 30 days IntelliPharm correlation with market (S&P 500)
1 Month Beta 1.07  
Highest Price:  
Lowest Price:  
2.2  
1.77  
April 29 2013 
May 17 2013 
IntelliPharm returns are very sensitive to returns on the market. As market goes up or down, IntelliPharm is expected to follow.
IntelliPharmaCeutics International Inc llmost one BetaIntelliPharmaCeutics Beta Legend
IPCI United States Nasdaq
IntelliPharmaCeutics International Inc
Healthcare
Drug Delivery
Benchmark S&P 500
http://www.intellipharmaceutics.com
Contact Number: 416. 798. 3001
Currency: USD - US Dollar
Traded on Nasdaq Capital Markets
    
Current Valuation42.53 M
Shares Outstanding19.72 M
Number of Shares Shorted133.14 K
Revenue107.09 K
 United States Nasdaq   0.97 % Macroaxis: 0.97 Moved Up  
 
 United States Russel   0.17 % Macroaxis: 0.17 Moved Up  
 
 United States NYSE   0.12 % Macroaxis: 0.12 Moved Up  
 
 thisGreen IPCI IPCI agains markets  0.00 % No Change  
 United States SP 500   0.07 % Macroaxis: 0.07 Moved Down  
 
Compare to Competition Get Alpha   Get Advice

IntelliPharm Leadership

Isa Odidi Chairman of the Board, CEO, MBA
MBA Odidi Co-Founder, Chairman, Chairman of Scientific Advisory Board, CEO and Co-Chief Scientific Officer
Shameze Rampertab CFO, Vice President - Finance, MBA
Amina Odidi President, COO, Principal Accounting Officer, Co-Chief Scientific Officer and Director, Ph.D

IntelliPharm Price and Market Media

The median price of IntelliPharm for the period between Sun, Apr 21, 2013 and Tue, May 21, 2013 is 1.97 with a coefficient of variation of 6.38. The daily time series for the period is distributed with a sample standard deviation of 0.13, arithmetic mean of 1.97, and mean deviation of 0.1. The Stock did not receive any noticable media coverage during the period.
IntelliPharm         SP 500
Price Growth (%)
 

IntelliPharm Summary

IntelliPharmaCeutics International Inc [IPCI] is traded on Nasdaq Capital Markets in USA. It is located in Toronto, ON MW X and employs 39 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 38.85 M. IntelliPharmaCeutics International Inc conducts business under Healthcare sector and is part of Drug Delivery industry. This company has 19.72 M outstanding shares of which 133.14 K shares are currently shorted by private and institutional investors with about 4.7 trading days to cover.
Intellipharmaceutics International Inc. engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada. more
Past Market
Over 30
Days
0
Out Of
100
 
Chance of
More
Than
96 %
 
Follow IntelliPharm with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add IntelliPharm to your reader
 

IntelliPharm Research Report

IntelliPharm vs. VRX

Correlation analysis and fundamentals comparison between IntelliPharmaCeutics and Valeant Pharmaceuticals

IntelliPharm Executives

CA MBA CFO and VP of Fin.

IntelliPharm Directors

Eldon Smith Independent Director
Bahadur Madhani Independent Director
Kenneth Keirstead Independent Director
Glenn Neumann Director of Investor Relations
MA, BASc VP of Legal Affairs and Licensing, Secretary, Director and Member of Corporate Governance Committee

IntelliPharm Fundamentals

Net Income vs Earnings Per Share
Book Value Per Share vs Current Asset
Net Income vs Revenue
Current Liabilities vs Current Asset

IntelliPharm vs Competition

IntelliPharm vs. Valeant Pharmaceuticals International Inc
IntelliPharm vs. Elan Corporation plc
IntelliPharm vs. Hospira Inc
IntelliPharm vs. Alkermes plc
IntelliPharm vs. PetMed Express Inc
IntelliPharm vs. Flamel Technologies SA
IntelliPharm vs. Acura Pharmaceuticals Inc
IntelliPharm vs. Delcath Systems Inc
IntelliPharm vs. Adamis Pharmaceuticals Corporation
IntelliPharm vs. Columbia Laboratories Inc

IntelliPharm May 21 2013 Opportunity Range

Downside Deviation3.2
Information Ratio(0.30)
Maximum Drawdown10.96
Value At Risk(4.83)
Potential Upside3.57

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium